Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Shares Outstanding (Diluted Average) (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $15.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 3.36% to $15.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, up 3.36% year-over-year, with the annual reading at $15.5 million for FY2025, 3.36% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $15.5 million at Inhibrx Biosciences, roughly flat from $15.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $15.5 million in Q4 2025, with the low at $10.9 million in Q2 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $14.0 million, with a median of $14.8 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 32.96% in 2024, then increased 3.36% in 2025.
  • Over 3 years, Shares Outstanding (Diluted Average) stood at $11.8 million in 2023, then rose by 27.17% to $15.0 million in 2024, then rose by 3.36% to $15.5 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $15.5 million, $15.5 million, and $15.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.